Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 14/11/2019 | Race reveals new strategy for cancer drug Bisantrene | Download |
| 24/10/2019 | Appendix 3Y-Dr Daniel Tillett | Download |
| 17/10/2019 | Notice of Annual General Meeting/Proxy Form | Download |
| 17/10/2019 | Annual Report to shareholders | Download |
| 17/10/2019 | Appendix 4C - quarterly | Download |
| 14/10/2019 | Appendix 3Y-Chris Ntoumenopoulos | Download |
| 14/10/2019 | Change in substantial holding | Download |
| 14/10/2019 | Appendix 3B | Download |
| 14/10/2019 | Cleansing Notice | Download |
| 14/10/2019 | Appendix 3Y-Dr Bill Garner | Download |
ASX: RAC
Price
Latest News
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug,
Dr Daniel Tillett joins Race Board
Prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has
Don't miss important updates
Get the latest news & announcement and stay up-to-date.